iRadimed (IRMD) Projected to Announce Earnings on Friday

iRadimed (NASDAQ:IRMD) is expected to release its Q2 2026 results before the market opens on Friday, July 31st. Analysts expect iRadimed to announce earnings of $0.42 per share and revenue of $20.35 million for the quarter. iRadimed has set its FY 2026 guidance at 2.060-2.210 EPS and its Q2 2026 guidance at 0.440-0.480 EPS. Parties can check the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Friday, July 31, 2026 at 11:00 AM ET.

iRadimed (NASDAQ:IRMD) last issued its earnings results on Friday, May 1st. The medical equipment provider reported $0.49 EPS for the quarter, beating analysts’ consensus estimates of $0.46 by $0.03. iRadimed had a net margin of 27.36% and a return on equity of 24.48%. The business had revenue of $21.98 million for the quarter, compared to the consensus estimate of $21.32 million.

iRadimed Trading Down 0.3%

Shares of NASDAQ IRMD opened at $94.83 on Wednesday. iRadimed has a 12-month low of $57.53 and a 12-month high of $107.90. The company has a market cap of $1.21 billion, a P/E ratio of 51.82 and a beta of 0.90. The stock has a fifty day moving average price of $94.44 and a 200 day moving average price of $95.80.

iRadimed Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, May 29th. Stockholders of record on Friday, May 15th were given a $0.20 dividend. The ex-dividend date of this dividend was Friday, May 15th. This represents a $0.80 annualized dividend and a dividend yield of 0.8%. iRadimed’s dividend payout ratio is presently 43.72%.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on IRMD shares. Freedom Capital upgraded iRadimed to a “strong-buy” rating in a research note on Thursday, April 2nd. Weiss Ratings cut iRadimed from a “buy (b)” rating to a “buy (b-)” rating in a report on Wednesday, May 20th. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat.com, iRadimed has a consensus rating of “Buy” and a consensus target price of $120.00.

Insiders Place Their Bets

In other news, CEO Roger E. Susi sold 5,000 shares of the firm’s stock in a transaction dated Monday, May 18th. The stock was sold at an average price of $87.51, for a total transaction of $437,550.00. Following the completion of the sale, the chief executive officer directly owned 2,175,000 shares in the company, valued at $190,334,250. This trade represents a 0.23% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 21,250 shares of company stock valued at $1,836,403. Corporate insiders own 34.60% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. boosted its stake in iRadimed by 1.0% during the 3rd quarter. Vanguard Group Inc. now owns 566,507 shares of the medical equipment provider’s stock valued at $40,313,000 after acquiring an additional 5,475 shares during the last quarter. T. Rowe Price Investment Management Inc. increased its position in shares of iRadimed by 410.7% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 255,887 shares of the medical equipment provider’s stock worth $24,893,000 after purchasing an additional 205,783 shares during the last quarter. Dimensional Fund Advisors LP increased its position in shares of iRadimed by 1.2% in the 4th quarter. Dimensional Fund Advisors LP now owns 217,129 shares of the medical equipment provider’s stock worth $21,123,000 after purchasing an additional 2,578 shares during the last quarter. Goldman Sachs Group Inc. raised its stake in shares of iRadimed by 37.0% in the 4th quarter. Goldman Sachs Group Inc. now owns 205,227 shares of the medical equipment provider’s stock valued at $19,964,000 after purchasing an additional 55,426 shares in the last quarter. Finally, State Street Corp lifted its position in shares of iRadimed by 3.1% during the fourth quarter. State Street Corp now owns 192,952 shares of the medical equipment provider’s stock worth $18,770,000 after purchasing an additional 5,713 shares during the last quarter. Hedge funds and other institutional investors own 92.34% of the company’s stock.

About iRadimed

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.